Jpmorgan Chase & CO Spero Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 236 shares of SPRO stock, worth $313. This represents 0.0% of its overall portfolio holdings.
Number of Shares
236
Previous 236
-0.0%
Holding current value
$313
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SPRO
# of Institutions
51Shares Held
15.5MCall Options Held
500Put Options Held
1K-
Anson Funds Management LP Dallas, TX3.75MShares$4.99 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.77MShares$2.35 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.8 Million14.54% of portfolio
-
Acadian Asset Management LLC Boston, MA1.07MShares$1.43 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny976KShares$1.3 Million0.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $46.6M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...